Alzamend Neuro, Inc. (NASDAQ:ALZN) Sees Significant Drop in Short Interest

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totalling 32,200 shares, a decrease of 48.8% from the December 31st total of 62,900 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average trading volume of 209,700 shares, the days-to-cover ratio is presently 0.2 days.

Alzamend Neuro Stock Up 1.4 %

NASDAQ ALZN opened at $1.14 on Thursday. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06. The firm’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $1.88.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Wednesday, December 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.38) by $1.98. As a group, sell-side analysts expect that Alzamend Neuro will post -1.68 earnings per share for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets decreased their price target on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Monday, December 16th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.